Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
4
×
boston blog main
boston top stories
clinical trials
4
×
life sciences
national blog main
rna interference
alnylam pharmaceuticals
aminolevulinic acid
drugs
fda
givosiran
national top stories
onpattro
patisiran
san francisco blog main
san francisco top stories
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akcea therapeutics
akin akinc
alexion pharmaceuticals
alnylam pharmaceutials
andrew fire
arrowhead pharmaceuticals
biotech
boehringer ingelheim
craig mello
deals
dicerna pharmaceuticals
eli lilly
hepatitis b
hereditary transthyretin amyloidosis
indiana blog main
indiana top stories
inotersen
john maraganore
johnson & johnson
neurodegenerative diseases
What
rnai
4
×
alnylam
drug
interference
medicine
pharmaceuticals
rna
ago
fda
gets
ok
second
seek
speedy
abandoning
afternoon
alnylam’s
approval
approved
baggage
cleared
companies
cuts
data
deal
development
dicerna
far
free
history
indicated
landmark
long
making
market
medicines
nasdaq
new
nod
onpattro
Language
Current search:
rnai
×
" clinical trials "
×
boston
×
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug